Cite
HARVARD Citation
Bilgin, B. et al. (2017). Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer. Future oncology. pp. 1911-1913. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bilgin, B. et al. (2017). Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer. Future oncology. pp. 1911-1913. [Online].